Ductal Carcinoma In Situ Management

Introduction to DCIS

DCIS sits between atypical ductal hyperplasia and invasive ductal carcinoma on the spectrum of breast proliferative abnormalities, representing an early, localized stage where neoplastic epithelial cells proliferate within the ductal structure of the breast but remain contained by the basement membrane 1
The disease accounts for approximately 20-25% of all screen-detected breast cancers in the United States, representing roughly 55,720-62,280 new cases annually 3, 2

DCIS most commonly presents as mammographically detected microcalcifications (90-98% of cases), typically pleomorphic and arranged in linear or segmental patterns 2
About 10% present as uncalcified masses on mammography 2
Definitive diagnosis requires pathologic evaluation because imaging cannot determine basement membrane invasion status 2

The NCCN guidelines provide three primary treatment pathways: lumpectomy with whole-breast radiation, total mastectomy with or without sentinel node biopsy, and lumpectomy alone without radiation 3, 1
Lumpectomy with whole-breast radiation reduces local recurrence risk by approximately 50-70% 4, 5, 2
Total mastectomy provides maximum local control with approximately 1% chest wall recurrence risk, but represents potential overtreatment for many patients 4

Tamoxifen reduces total breast cancer incidence from 13.4% to 8.2%, with particular benefit in reducing invasive cancer in the ipsilateral breast (from 4.2% to 2.1% at 5 years) 1
Tamoxifen benefit is primarily seen in estrogen receptor-positive DCIS 1

DCIS has a 10-year overall survival rate of 97.2-98.6% when appropriately managed 2
Approximately 25-60% of DCIS lesions progress to invasive ductal carcinoma if left untreated 4
Following breast-conserving therapy, approximately 50% of recurrences manifest as invasive cancer rather than DCIS 4

Risk factors for progression include larger lesion size, younger age, and HER2 overexpression 2
Nuclear grade, presence of comedo necrosis, and margin involvement are the most commonly used predictors, but these remain imperfect 2
A meta-analysis found that 25.9% of cases diagnosed as pure DCIS on core biopsy are upstaged to invasive cancer at surgical excision 2